IL152896A0 - Cancer treatments by using a combination of an antibody against her2 and interleukin-2 - Google Patents
Cancer treatments by using a combination of an antibody against her2 and interleukin-2Info
- Publication number
- IL152896A0 IL152896A0 IL15289601A IL15289601A IL152896A0 IL 152896 A0 IL152896 A0 IL 152896A0 IL 15289601 A IL15289601 A IL 15289601A IL 15289601 A IL15289601 A IL 15289601A IL 152896 A0 IL152896 A0 IL 152896A0
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- combination
- antibody against
- cancer treatments
- against her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20428400P | 2000-05-15 | 2000-05-15 | |
US09/855,342 US7306801B2 (en) | 2000-05-15 | 2001-05-14 | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
PCT/US2001/015525 WO2001087336A1 (en) | 2000-05-15 | 2001-05-15 | Cancer treatments by using a combination of an antibody against her2 and interleukin -2 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152896A0 true IL152896A0 (en) | 2003-06-24 |
Family
ID=26899337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15289601A IL152896A0 (en) | 2000-05-15 | 2001-05-15 | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7306801B2 (xx) |
EP (1) | EP1282442A1 (xx) |
JP (1) | JP2004501101A (xx) |
AU (1) | AU2001261569A1 (xx) |
CA (1) | CA2408974A1 (xx) |
IL (1) | IL152896A0 (xx) |
WO (1) | WO2001087336A1 (xx) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030007640A (ko) * | 2000-05-19 | 2003-01-23 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
EP1341902A2 (en) * | 2000-12-08 | 2003-09-10 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
AU2004217434B2 (en) * | 2000-12-08 | 2010-08-26 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
AU2002351353A1 (en) * | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
CA2472186A1 (en) * | 2002-01-18 | 2003-07-31 | Chiron Corporation | Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
DK1531850T3 (da) * | 2002-06-07 | 2012-06-04 | Zymogenetics Inc | Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere |
EP2357005A1 (en) | 2002-07-01 | 2011-08-17 | Wilex AG | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
CA2566745A1 (en) * | 2004-05-20 | 2005-12-01 | Zymogenetics, Inc. | Methods of treating cancer using il-21 and monoclonal antibody therapy |
PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
CN102886045A (zh) * | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
NZ590431A (en) | 2005-02-23 | 2012-08-31 | Genentech Inc | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
CA2599445C (en) * | 2005-03-09 | 2022-05-03 | Abbott Laboratories | Diagnostics method for identifying candidate patients for the treatment with trastuzumab |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
EP3488866A1 (en) * | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
US20070111906A1 (en) * | 2005-11-12 | 2007-05-17 | Milner Jeffrey L | Relatively low viscosity transmission fluids |
EP2463305B1 (en) | 2006-01-12 | 2016-05-11 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
AU2007281774A1 (en) * | 2006-08-04 | 2008-02-14 | Astrazeneca Ab | Human antibodies to ErbB 2 |
MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
SI2171090T1 (sl) | 2007-06-08 | 2013-07-31 | Genentech, Inc. | Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje |
US9551033B2 (en) * | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CA2694121C (en) * | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US20090312360A1 (en) | 2008-06-17 | 2009-12-17 | Wyeth | Antineoplastic Combinations Containing HKI-272 and Vinorelbine |
JP5681108B2 (ja) | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | 4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ |
CN102753193A (zh) | 2008-10-31 | 2012-10-24 | 比奥根艾迪克Ma公司 | Light靶向分子及其用途 |
EP2408817B1 (en) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Bispecific anti-her antibodies |
CA2755789C (en) | 2009-04-06 | 2016-01-19 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
IN2012DN06309A (xx) | 2010-01-11 | 2015-09-25 | Alexion Pharma Inc | |
NZ601580A (en) | 2010-02-11 | 2014-11-28 | Alexion Pharma Inc | Therapeutic methods using anti-cd200 antibodies |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
CA2865082A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
KR101453462B1 (ko) * | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
WO2015138435A1 (en) | 2014-03-11 | 2015-09-17 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
CN106414503A (zh) | 2014-03-11 | 2017-02-15 | 分子模板公司 | 包含邻近氨基酸端的志贺毒素a亚基效应子区和细胞靶向性免疫球蛋白型结合区的蛋白 |
MX2016012830A (es) | 2014-04-11 | 2017-01-05 | Medimmune Llc | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. |
US9586056B2 (en) | 2014-07-03 | 2017-03-07 | Haniva Llc | Combination therapy for treating cancer and method for treating cancer using a combination therapy |
WO2016052971A1 (ko) * | 2014-09-30 | 2016-04-07 | 가톨릭대학교 산학협력단 | 유방암 진단용 허셉틴-광감각제 접합체 및 이의 제조 방법 |
CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
KR20180030085A (ko) | 2015-07-26 | 2018-03-21 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
AU2018213194B2 (en) | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
KR20190129077A (ko) | 2017-03-15 | 2019-11-19 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
JPS6360942A (ja) * | 1986-08-01 | 1988-03-17 | シタス コ−ポレイシヨン | インタ−ロイキン−2と共に免疫毒素又は抗体を用いてのコンビネ−ション治療 |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
CA2472186A1 (en) * | 2002-01-18 | 2003-07-31 | Chiron Corporation | Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
-
2001
- 2001-05-14 US US09/855,342 patent/US7306801B2/en not_active Expired - Fee Related
- 2001-05-15 WO PCT/US2001/015525 patent/WO2001087336A1/en active Application Filing
- 2001-05-15 CA CA002408974A patent/CA2408974A1/en not_active Abandoned
- 2001-05-15 IL IL15289601A patent/IL152896A0/xx unknown
- 2001-05-15 EP EP01935476A patent/EP1282442A1/en not_active Ceased
- 2001-05-15 JP JP2001583803A patent/JP2004501101A/ja active Pending
- 2001-05-15 AU AU2001261569A patent/AU2001261569A1/en not_active Abandoned
-
2007
- 2007-08-02 US US11/888,699 patent/US20080159981A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2408974A1 (en) | 2001-11-22 |
US20020031515A1 (en) | 2002-03-14 |
EP1282442A1 (en) | 2003-02-12 |
WO2001087336A1 (en) | 2001-11-22 |
JP2004501101A (ja) | 2004-01-15 |
US7306801B2 (en) | 2007-12-11 |
US20080159981A1 (en) | 2008-07-03 |
AU2001261569A1 (en) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL152896A0 (en) | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 | |
AU2002348477A1 (en) | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies | |
EP1383801A4 (en) | ANTIBODIES AGAINST CANCER | |
HUP0501113A3 (en) | Cripto blocking antibodies and uses thereof | |
AU2002244968A1 (en) | Anti-osteopontin antibody and use thereof | |
EP1572131A4 (en) | ANTIBODY THERAPY | |
PL366469A1 (en) | Anti-osteopontin antibody and use thereof | |
EP1372736A4 (en) | PREPARATIONS AGAINST CANCER FORMATION | |
AU2001256325A1 (en) | Human and humanized fap-alpha-specific antibodies | |
AU2001290860A1 (en) | Spas-1 cancer antigen | |
AU2001260876A1 (en) | Radiation therapy device with miniaturized radiation source | |
AU2003227148A8 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
HUP0400775A2 (en) | Specific human antibodies for selective cancer therapy | |
AU2002351374A1 (en) | Antibodies to treat cancer | |
EP1385879A4 (en) | DIAGNOSIS AND THERAPY OF CANCER OF REPRODUCTIVE ORGANS | |
AU2002227272A1 (en) | Ovarian tumor antigen and methods of use therefor | |
AU2003219696A8 (en) | Sga-1m, a cancer associated antigen, and uses thereof | |
EP1454914A4 (en) | TUMOR ANTIGEN | |
AU7832700A (en) | Ovarian tumor antigen and methods of use therefor | |
AU2002340850A1 (en) | Antigen mimotopes and vaccine against cancers | |
AU5632500A (en) | Cancer associated antigens and uses therefor | |
AU2002351382A1 (en) | Combination cancer therapy | |
AUPR589001A0 (en) | An antibody cancer therapeutic | |
AU2001272529A1 (en) | Monoclonal antibody against human cathepsin w | |
AU5162400A (en) | Cancer associated antigens and uses therefor |